rucaparib
Selected indexed studies
- Rucaparib. (, 2006) [PMID:29999967]
- Rucaparib or Physician's Choice in Metastatic Prostate Cancer. (N Engl J Med, 2023) [PMID:36795891]
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). (J Clin Oncol, 2022) [PMID:35658487]
_Worker-drafted node — pending editorial review._
Connections
rucaparib is a side effect of
Sources
- Rucaparib. (2006) pubmed
- Rucaparib or Physician's Choice in Metastatic Prostate Cancer. (2023) pubmed
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). (2022) pubmed
- Rucaparib: A Review in Ovarian Cancer. (2019) pubmed
- Rucaparib. (2012) pubmed
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. (2021) pubmed
- Rucaparib: First Global Approval. (2017) pubmed
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) pubmed
- Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. (2025) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. (2022) pubmed